MONTREAL, June 23, 2020 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an important clarification about Bioganix CleanCare, its brand of disinfection and wellness products.

On. June 19, 2020, the FDA issued a public health warning about nine (9) hand sanitizers manufactured by Eskbiochem SA, four (4) “CleanCare No Germ Advanced” branded products that could contain potentially dangerous chemicals.

This FDA warning about Eskbiochem SA is 100% UNRELATED to BIOGANIX CLEANCARE.

Relevium and its executive team would like to provide comfort to its customers and shareholders that there is ZERO relation between Bioganix CleanCare, the nine products recalled and its manufacturer, who uses a similar name for some of its products.

Our Bioganix CleanCare disinfection products are manufactured at our partner contract manufacturers located in the US and Canada. Bioganix only contracts FDA and Health Canada approved facilities, following good manufacturing practices and the Bioganix CleanCare disinfection products are formulated using only accepted medical grade ingredients that meet or exceeded national and international standards.

Aurelio Useche CEO of Relevium stated: “We are very pleased to be able to distance ourselves from any product and manufacturer that does not meet top tier status for quality and safety track record. Our investors and customers alike can rest assured that our products meet the highest level of quality in terms of ingredients, manufacturing process and formulation”

Aurelio Useche stated further: “There is ZERO link between Bioganix CleanCare and ANY other CleanCare branded product in the market. There is only ONE Bioganix CleanCare and we stand behind our brand and its tradition for excellence”

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
                                                                                              
About Relevium Technologies

Relevium is a publicly traded Company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition, and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe.

Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical Company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions, or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release:

Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC

Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn